Tikun Olam ("Repair the World" in Hebrew) is the first, largest and foremost supplier of medical Cannabis in Israel, and globally recognized as the pioneer of modern medical cannabis.
Leaders in Research
One of the most important aspects of our work is our involvement in research studies that examine the application of our cannabis strains and products in treating patients with various conditions and symptoms.
Our research initiatives are published in professional medical journals with the goal of sharing knowledge and spreading awareness about the benefits of medical cannabis treatment and our belief in the importance of professional transparency and open collaboration.
Operating for over a decade, Tikun Olam's products have been used in ongoing clinical trials in Israel's regulated medical cannabis market, treating over 20,000 patients for a variety of medical conditions. Tikun Olam's peer-reviewed scientific research and unprecedented accumulated clinical data, achieved exceptional results and unparalleled success.
Professor Zvi Bentwich, our chief scientist, is a physician clinical immunologist and world-renowned expert on AIDS research, with vast clinical, educational and biomedical research experience.
He was the first physician to deal with AIDS in Israel since 1982, and founded the first and largest AIDS center in the country. Professor Bentwich is Professor Emeritus of Medicine of the Hebrew University Hadassah Medical School and currently, Professor of Microbiology Immunology and Genetics, and head of the Center for Emerging Tropical Diseases & AIDS, at the Ben Gurion University.
He is author of over 270 peer reviewed scientific publications.
Between 2002-2009, Dr. Bentwich was chief scientist of Rosetta Genomics Inc, (NASDAQ ROSG) and since 2012 he is the scientific director of the Ein Gedi – Dead Sea Arava Science Center where he is deeply involved in studies of medicinal plants and the skin microbiome.
Professor Bentwich has been board member (2002-2014) and chairman (2010-2012) of Physicians for Human Rights, Israel. Among other awards, he has received in 2010 a lifetime award from the Israeli Knesset for his contributions to Israel Medicine and Medical Sciences.
Lihi Bar-Lev Schleider, MA, is the founder of the research department at Tikun Olam.
She received her Master of Arts in Psychobiology at the Tel Aviv University and is currently a PhD student in medicine at the clinical research centre in Soroka hospital and Ben Gurion University. As a medical director in Tikun-Olam, Lihi lead all stages of clinical trials, including writing research protocols, and initiating, monitoring and analyzing the data of the clinical trials and studies. Three studies were published, three completed, and 15 are currently in process. In addition, Lihi manages all data collection of Tikun-Olam's patients (about 20,000 patients and an increase of approximately 250-300 patients per month).
She facilitated the analysis of this data to match specific varieties of cannabis to specific symptoms, conditions, and target populations, including finding effective doses and identifying side effects.
2006 - Company Established in Northern Israel.
2014 - Co founded Medreleaf pioneers in the Canadian medical cannabis industry.
2016 - Established Tikun Olam USA operating in Delaware, Nevada, Washington, Rhode Island, Maryland, Massachusetts, Illinois and California.
2017 - Co founded Medifarm Australia; Queensland’s first licensed medicinal cannabis developer.
2017 - Established Tikun Olam MC Ltd; bringing Tikun Olam’s unique knowledge and experience to the U.K.